ClinicalTrials.gg
CompletedNCT05895565Updated Nov 25, 2025

A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

A Phase 1 interventional study of PMG1015 and PMG1015 placebo in IPF, sponsored by Pulmongene Ltd.. Completed at 7 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Pulmongene Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

This is a phase 1b randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study of PMG1015 in idiopathic pulmonary fibrosis (IPF) subjects. This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after MAD.

02

Conditions studied

  • IPF
03

In context

Lead sponsor

Pulmongene Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of IPF as defined by current American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT) Clinical Practice Guidelines for IPF (2022) (Pathological examination refers to transbronchial lung cryobiopsy or surgical/pleuroscopic lung );
  2. Forced vital capacity percent predicted (FVCpp) ≥45% at screening;
  3. Diffusing capacity of the lung for carbon monoxide (DLCO; corrected for ) from 30% to 90% of the predicted, inclusive at screening;
  4. Subjects not receiving any approved IPF treatment (pirfenidone or nintedanib) within 1 month before enrollment for any reasons

Key Exclusion Criteria:

  1. Patients with instable condition of IPF as assessed by the investigator at screening, and those with acute exacerbation of IPF during screening or within 3 months prior to randomization;
  2. Patients who are likely to be lung transplant recipients within 6 months or expected to survive less than 1 year as assessed by the investigator at screening;
  3. Patients accompanying with an interstitial lung disease other than IPF;
  4. Patients accompanying with other types of respiratory disorders, which may affect the study results as assessed by the investigator;
  5. Patients who received vasodilator therapy for pulmonary arterial hypertension (e.g. Bosentan) within 1 month prior to screening;
  6. Patients accompanying with other uncontrolled underlying diseases, for which the patient is not considered suitable for the study as assessed by the investigator;
  7. Patients who had active tuberculosis within 12 months prior to screening, or clinical symptoms of bacterial, viral, fungal or microbial infections requiring intervention within 4 weeks prior to randomization;
  8. Patients who have known allergic reaction to the product or its active pharmaceutical ingredients (APIs), or history of allergic reaction to human, humanized, chimeric, or murine monoclonal antibodies or any substances contained in the ;
  9. Pregnant or lactating women; female subjects who plan to become pregnant during the study, or patients who are not willing to take measures as required by the protocol during the study;
  10. Other conditions that preclude the patient from participating in the study as assessed by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    PMG1015

    Drug: PMG1015

  • Placebo comparator
    Placebo Comparator

    Drug: PMG1015 placebo

Interventions

  • DrugPMG1015

    Including 3 dose levels: level 1, level 2 and level 3

  • DrugPMG1015 placebo

    Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3

06

What researchers measure

Primary outcomes

  1. The incidence of treatment-emergent adverse events (TEAEs)

    An Adverse Event (AE) is any event, side-effect or any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occur following the start of treatment.

    Time frame: Approximately 170 days.

  2. The severity of treatment-emergent adverse events (TEAEs)

    Severity of TEAEs (Grade 1 to 5) will be assessed based on NCI-CTCAE V5.0.

    Time frame: Approximately 170 days.

  3. The incidence of serious adverse events (SAEs)

    A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of medicinal product that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or results in congenital anomaly/birth defect.

    Time frame: Approximately 170 days.

  4. The severity of serious adverse events (SAEs)

    A serious adverse event (SAE) is defined as an AE occurring during any study phase and at any dose of medicinal product that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, or results in congenital anomaly/birth defect.

    Time frame: Approximately 170 days.

  5. Assessment of pulmonary function test results-forced vital capacity (FVC)

    Pulmonary function test is a test to explore the functional status of human respiratory system with the knowledge of exercise respiratory physiology and modern examination technology. Forced vital capacity (FVC) (mL) will be measured at Visits 1, 8, 14 and 16, to assess the changes in FVC from baseline to post-dose.

    Time frame: Approximately 170 days.

  6. Assessment of pulmonary function test results-forced vital capacity percent predicted (FVCpp)

    Pulmonary function test is a test to explore the functional status of human respiratory system with the knowledge of exercise respiratory physiology and modern examination technology. Forced vital capacity percent predicted (FVCpp) (%) will be measured at Visits 1, 8, 14 and 16, to assess the changes in FVCpp from baseline to post-dose.

    Time frame: Approximately 170 days.

  7. Assessment of pulmonary function test results-forced expiratory volume in 1 second (FEV1)

    Pulmonary function test is a test to explore the functional status of human respiratory system with the knowledge of exercise respiratory physiology and modern examination technology. Forced expiratory volume in 1 second (FEV1) (L) will be measured at Visits 1, 8, 14 and 16, to assess the changes in FEV1 from baseline to post-dose.

    Time frame: Approximately 170 days.

  8. Assessment of pulmonary function test results-diffusing capacity of the lungs for carbon monoxide (DLCO)

    Pulmonary function test is a test to explore the functional status of human respiratory system with the knowledge of exercise respiratory physiology and modern examination technology. Diffusing capacity of the lungs for carbon monoxide (DLCO) (mL/min/mmHg) will be measured at Visits 1, 8, 14 and 16, to assess the changes in DLCO from baseline to post-dose.

    Time frame: Approximately 170 days.

  9. Assessment of pulmonary function test results-diffusing capacity of the lungs for carbon monoxide percent predicted (DLCOpp)

    Pulmonary function test is a test to explore the functional status of human respiratory system with the knowledge of exercise respiratory physiology and modern examination technology. Diffusing capacity of the lungs for carbon monoxide percent predicted (DLCOpp) (DLCO%) will be measured at Visits 1, 8, 14 and 16, to assess the changes in DLCOpp from baseline to post-dose.

    Time frame: Approximately 170 days.

Secondary outcomes

  1. Evaluate the area under the serum drug concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of PMG1015.

    AUC is a pharmacokinetic parameter that represents the concentration of a drug in the blood at a certain time.

    Time frame: Approximately 170 days.

  2. Evaluate the area under the serum drug concentration-time curve from time zero to infinity (AUC0-∞) of PMG1015.

    AUC is a pharmacokinetic parameter that represents the concentration of a drug in the blood at a certain time.

    Time frame: Approximately 170 days.

  3. Evaluate the area under the concentration-time curve from time zero to the end of a dosing interval (AUC0-tau) of PMG1015.

    AUC is a pharmacokinetic parameter that represents the concentration of a drug in the blood at a certain time.

    Time frame: Approximately 170 days.

  4. Evaluate the maximum concentration (Cmax) of PMG1015.

    Cmax refers to the highest concentration of a drug in the blood after administration, which is related to the dose, route of administration, dosing frequency, and time to reach the peak concentration.

    Time frame: Approximately 170 days.

  5. Evaluate the time to reach the maximum concentration (Tmax) of PMG1015.

    Tmax refers to the time when a drug reaches its maximum concentration and exhibits its maximum effect in the body.

    Time frame: Approximately 170 days.

  6. Evaluate the half-life (t1/2) of PMG1015.

    t1/2 refers to the time required for the drug concentration in the blood to decrease by half.

    Time frame: Approximately 170 days.

  7. Evaluate the clearance rate (CL) of PMG1015.

    CL is the volume of blood that is completely cleared of a drug per unit time by the excretory organs, and its unit is usually mL·(min·kg)-1 or L·(h·kg)-1.

    Time frame: Approximately 170 days.

  8. Evaluate the distribution volume (Vz) of PMG1015.

    Vz is a pharmacokinetic parameter that reflects the extent of drug distribution in various tissues in the body.

    Time frame: Approximately 170 days.

  9. Evaluate the elimination rate constant (λz) of PMG1015.

    λz is referred to as the elimination rate constant, which is defined as the ratio of the amount of compound eliminated per unit time to the total amount, with its unit being the reciprocal of time.

    Time frame: Approximately 170 days.

  10. Correlation between the dose and exposure.

    Dose refers to the quantity of drug administered at one time to achieve the desired therapeutic effect, and it can vary depending on the patient's needs and medical condition.

    Time frame: Approximately 170 days.

  11. Incidence of PMG1015-induced and PMG1015-boosted ADAs.

    Immunogenicity assessment is mainly based on anti-drug antibodies (ADAs), including the incidence of PMG1015-induced and PMG1015-boosted ADAs.

    Time frame: Approximately 170 days.

07

Study locations

7 sites
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510120, China
  • Tongji Hospital Tongji Medical College of HUST
    Wuhan, Hubei 430030, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Feb 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Jun 8, 2023
StartActual
May 19, 2023
Primary completionActual
Feb 7, 2025
CompletionActual
Feb 7, 2025
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05895565
Lead sponsor
Pulmongene Ltd.
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
May 19, 2023
Primary completion
Feb 7, 2025
Completion
Feb 7, 2025
Last update
Nov 25, 2025

Study contacts

Wang
principal investigator · China-Japan Friendship Hospital
Dai
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion